Olema Pharmaceuticals
OLMA
66 hedge funds and large institutions have $81.2M invested in Olema Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 19 reducing their positions, and 13 closing their positions.
1,163% more call options, than puts
Call options by funds: $101K | Put options by funds: $8K
0% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 19
0.56% less ownership
Funds ownership: 82.54% → 81.98% (-0.56%)
10% less funds holding
Funds holding: 73 → 66 (-7)
12% less capital invested
Capital invested by funds: $92.1M → $81.2M (-$10.8M)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$1.82M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.63M |
| 3 |
Vontobel Holding
Zurich,
Switzerland
|
+$1.54M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$1.5M |
| 5 |
MAM
Monaco Asset Management
Monaco
|
+$485K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$3.4M |
| 2 |
Janus Henderson Group
London,
|
-$990K |
| 3 |
JP Morgan Chase
New York
|
-$820K |
| 4 |
BlackRock
New York
|
-$755K |
| 5 |
Two Sigma Advisers
New York
|
-$461K |
OLMA Hedge Fund Activity: Q4 2022 in Review
66 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q4 2022, worth a combined $81.2M — down 12% from $92.1M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of OLMA and 7 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 19 added.
The largest buyer was Kynam Capital Management, adding an estimated $1.82M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $3.4M sold.
- 66 institutional investors held Olema Pharmaceuticals (OLMA) as of Q4 2022, down from 73 in Q3 2022.
- Funds reported $81.2M of Olema Pharmaceuticals stock for Q4 2022, down 12% quarter-over-quarter.
- 7 funds opened new Olema Pharmaceuticals positions in Q4 2022 and 13 closed out, a net change of -6 holders.
- The largest Olema Pharmaceuticals buyer in Q4 2022 was Kynam Capital Management, an estimated $1.82M added.
- The largest Olema Pharmaceuticals seller in Q4 2022 was Fairmount Funds Management, an estimated $3.4M sold.
Based on aggregated 13F filings for Q4 2022.